 | | Vol. 12.00 – 5 January, 2021 |
| |
|
|
| Scientists report a key β cell-macrophage crosstalk pathway mediated by the miRNA-29-TNF-receptor-associated factor 3 (TRAF3) axis.
[Cell Reports] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| | | The authors examined the role of pancreatic islets in Cadmium (Cd)-induced hyperglycemia. They showed that within whole pancreatic tissue, Cd selectively accumulated in pancreatic islets and caused altered islet function that likely contributed to dysglycemia.
[International Journal of Molecular Sciences] |
| |
|
|
| Using genetic lineage tracing with a dual-recombinase system and live imaging, investigators showed that Dclk1+ tumor cells continuously provided progeny cells within pancreatic intraepithelial neoplasia, primary and metastatic PDAC, and PDAC-derived spheroids in vivo and in vitro.
[eLife] |
|
|
|
| Researchers demonstrated that S100A16 promoted PDAC cell proliferation, migration, invasion, and metastasis both in vitro and in vivo. Knockdown of S100A16 induced PDAC cell cycle arrest in the G2/M phase and apoptosis.
[Cell Biology and Toxicology] |
|
|
|
| Using genetic lineage tracing with a dual-recombinase system and live imaging, investigators showed that DCLK1+ tumor cells continuously provided progeny cells within pancreatic intraepithelial neoplasia, primary and metastatic PDAC, and PDAC-derived spheroids in vivo and in vitro.
[eLife] |
|
|
|
| Researchers demonstrated that S100A16 promoted PDAC cell proliferation, migration, invasion, and metastasis both in vitro and in vivo. Knockdown of S100A16 induced PDAC cell cycle arrest in the G2/M phase and apoptosis.
[Cell Biology and Toxicology] |
|
|
|
| Investigators report the design and synthesis of 57 nonsecosteroidal vitamin D receptor (VDR) modulators based on the skeleton of phenyl-pyrrolyl pentane. Compounds C4, I5, and I8 exhibited excellent VDR affinity and effective inhibition of the activation of pancreatic stellate cells (PSCs), as well as potent suppression of the interaction between cancer cells and PSCs in vitro.
[Journal of Medicinal Chemistry] |
|
|
|
| Scientists determined the feasibility of Mucin 1 (MUC1)-based targeted radionuclide therapy for PDAC, by evaluating the expression profile of MUC1 in different pancreatic cells and tissues using the C595 antibody.
[Cancers] |
|
|
|
|
An integrated analysis of transcriptional profiles revealed many differentially expressed long non-coding RNAs (lncRNAs) involved in PDAC aerobic glycolysis.
[International Journal of Biological Sciences] |
| | Researchers analyzed 4-(N)-stearoyl-gemcitabine cytotoxic activity, intracellular uptake, apoptosis, necrosis, and autophagy induction in both Panc1 cell line and their derived cancer stem cells.
[International Journal of Molecular Sciences] |
|
|
|
| While PanIN cells expressed oncogenic KRas and have increased activity of epidermal growth factor receptor (EGFR), the authors demonstrated that in DCLK1+ PanIN cells EGFR signaling was not propagated to the nucleus.
[iScience] |
|
|
|
|
| Investigators highlight advances that provide a new perspective for the understanding of the β-cell failure that triggers type 2 diabetes.
[Nature Reviews Molecular Cell Biology] |
|
|
|
| Unresolved chronic endoplasmic reticulum (ER) stress is a major contributor to beta-cell loss of function and identity. Restoring ER homeostasis, enhancing ER-associated degradation of misfolded protein, and boosting chaperoning activity, are emerging therapeutic approaches for diabetes treatment.
[Trends in Pharmacological Sciences] |
|
|
|
| The authors focus on the pre-clinical and clinical evidence of novel ways to take advantage of the type I IFN pathway, such as IFN based conjugates and activation of the STING and RIG-I pathways.
[Critical Reviews in Oncology/Hematology] |
|
|
|
|
| Provention Bio, Inc announced that the BLA for Teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals has been filed by the FDA. The FDA also granted Provention’s request for Priority Review and assigned a user fee goal date of July 2, 2021, under the Prescription Drug User-Fee Act.
[Provention Bio, Inc] |
|
|
|
| The FDA authorized marketing of the EndoRotor System to resect and remove necrotic tissue for patients with walled-off pancreatic necrosis, a potentially deadly condition which can occur several weeks after an episode of severe acute pancreatitis, often requiring tissue removal.
[FDA] |
| | Pfizer Inc. and OPKO Health Inc.fizer Inc. announced that the FDA has accepted for filing the initial Biologics License Application for Somatrogon, a long-acting human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency.
[OPKO Health Inc.] |
|
|
| | | January 7 – 8, 2021
Virtual |
|
|
| | | | | Rutgers University – New Brunswick, New Jersey, United States |
|
|
| | | University of Southern Denmark – Odense M, Denmark |
|
|
| | | University of Cincinnati – Cincinnati, Ohio, United States |
|
|
| | | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
| | | Harvard Joslin Diabetes Center – Boston, Massachusetts, United States |
|
|
| |
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
